Clinical trials: Hormonal Contraception
- Condition Hormonal Contraception
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Contraception
A Multicentre, Prospective, Open-label, Non-comparative Study
As there are no recent studies conducted in Italy on the profile of this COC, the purpose of this study is to evaluate its efficacy and tolerability in a given subset of women residing in Italy that are in need of contraception.
- Trial name
- NCT06067256
- Testing
- Female Contraceptive
- Where
- Italy
- Volunteers
- 228 people, healthy volunteers welcome
- Sponsor
- Italfarmaco
Contraception
Safety, Efficacy, Tolerability and Pharmacokinetics of LF111 (Drospirenone 4.0 mg) During 13 Cycles
To demonstrate the contraceptive efficacy of LF111 . To demonstrate the safety and tolerability of LF111 and assessment of pharmacokinetics of LF111.
- Trial name
- NCT02269241
- Testing
- LF111 (drospirenone)
- Where
- 37 sites in United States
- Volunteers
- 1,552 people, healthy volunteers welcome
- Sponsor
- Laboratories Leon Farma, S.A.
Contraception, Female Contraception
Relative Risks for Non-fatal Venous Thromboembolism, Ischemic Stroke and Myocardial Infarction in Users of ORTHO EVRA(Norelgestromin and Ethinyl Estradiol Contraceptive Patch) Compared to Levonorgestrel-containing Oral Contraceptives.
This study uses the PharMetrics and MarketScan US health care insurance claims database to estimate relative risks for non-fatal venous thromboembolism (including cerebral venous sinus thrombosis), ischemic stroke, and acute…
- Conditions
- Contraception, Female Contraception, Fertility Control
- Trial name
- NCT00511784
- Volunteers
- 440 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Contraception
YAZ, Oral Contraceptive Registration in China
The purpose of this study is to evaluate the effectiveness in terms of prevention of pregnancy and safety of the oral contraceptive YAZ in healthy Chinese women.
- Trial name
- NCT00819312
- Testing
- YAZ (SH T00186, BAY86-5300)
- Where
- 17 sites in China, Hong Kong
- Volunteers
- 675 people, healthy volunteers welcome
- Sponsor
- Bayer
Contraception
An Open-label Study to Evaluate Contraceptive Efficacy and Safety of the Transdermal Contraceptive System of Norelgestromine and Ethinyl Estradiol
The purpose of this study is to evaluate the contraceptive efficacy, safety, cycle control, compliance, and subject satisfaction of the transdermal contraceptive system, norelgestromine and ethinyl estradiol (NLGM / EE).
- Trial name
- NCT00307632
- Testing
- Norelgestromine (NLGM)/ethinyl estradiol (EE)
- Where
- 12 sites in Brazil, Mexico
- Volunteers
- 580 people, healthy volunteers welcome
- Sponsor
- Janssen-Cilag Farmaceutica Ltda.
Contraception, Female Contraception
Evaluation of Women's Experience With EVRA (Norelgestromin + Ethinyl Estradiol) Transdermal Contraceptive Patch Compared With Previous Methods of Contraception.
The purpose of the study is to evaluate user experience with the EVRA® Contraceptive Transdermal Patch; specifically, user satisfaction with the EVRA® Patch, and if applicable, user preference of the EVRA® Patch compared with…
- Trial name
- NCT00261482
- Testing
- norelgestromin + ethinyl estradiol
- Volunteers
- 778 people, healthy volunteers welcome
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Contraception, Female Contraception
Postmarketing Study of ORTHO EVRA (Norelgestromin and Ethinyl Estradiol Contraceptive Patch) in Relation to Venous Thromboembolism (Blood Clots), Stroke and Heart Attacks
The purpose of the study is to assess the occurrence of venous thromboembolism (blood clots), stroke, and heart attack in current users of ORTHO EVRA compared to current users of norgestimate-containing oral contraceptives with…
- Trial name
- NCT00331071
- Testing
- Monophasic or triphasic Oral contraceptive tablet, Ortho Evra transdermal patch containing 6 mg NGMN/0.75 mg EE
- Volunteers
- 334 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Male Contraception
Open Label, Dose Escalation, Repeat Dose Study Evaluating YCT-529 in Healthy Males
This is a Phase 1b/2a open-label, dose escalation 3 part-study, 28-day, 90-day or 180 day repeat dose study of YCT-529 in healthy males who have decided to have a vasectomy and are waiting for the procedure and for men who have…
- Trial name
- NCT06542237
- Testing
- YCT-529
- Where
- New Zealand
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- YourChoice Therapeutics, Inc.
Contraception
Hormonal Contraception in Healthy Young Men (P42306)(COMPLETED)(P06057)
Male volunteers receive a new hormonal contraceptive consisting of an implant releasing a hormone and hormone injections in order to investigate the suppressive effect on sperm production and reversibility of sperm production…
- Trial name
- NCT00403793
- Testing
- etonogestrel with testosterone undecanoate
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- Organon and Co
Contraception, Female Contraception
A Study of Efficacy and Safety With the Transdermal Contraceptive System Versus Triphasil.
The purpose of the study was to compare the contraceptive efficacy and safety of the transdermal patch to Triphasil.
- Trial name
- NCT00236795
- Testing
- norelgestromin + ethinyl estradiol; triphasil.
- Volunteers
- 1,494 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Contraception
Safety and Acceptability Study of a Non-Hormonal Ring
This is a feasibility, multi-center, open-label, non-significant risk device study for a non-hormonal contraceptive ring.
- Trial name
- NCT03598088
- Testing
- Ovaprene
- Where
- 6 sites in United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Daré Bioscience, Inc.
Male Contraception, Semen Volume
Effects of NLS-133, a Potential Non-Hormonal "On-Demand" Male Contraceptive
NLS-133-CLIN001 is a Phase 2a study designed to assess the safety, tolerability, and effects of NLS-133 (combination of two FDA-approved agents) compared to an active control (FDA-approved pharmacologic agent) or placebo on semen…
- Conditions
- Male Contraception, Semen Volume, Sperm Motility
- Trial name
- NCT07393334
- Testing
- NLS-133, Active Comparator #1
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Next Life Sciences
Contraception
A Study to Compare 3 Doses of a Hormonal Intra-uterine Device Containing Levonorgestrel and Indomethacin With a Hormonal Intra-uterine Device Containing Only Levonorgestrel to Assess the Effect and Safety of the Combined Components
This study is the first study investigating the combined intrauterine administration of LNG (levonorgestrel) and IND (indomethacin). It is a combined proof-of-concept (PoC) and dose finding (DF) study in pre-menopausal women.
- Trial name
- INDessa (NCT03562624)
- Testing
- BAY98-7443, Levonogestrel (Skyla, BAY86-5028)
- Where
- 7 sites in Germany, United Kingdom
- Volunteers
- 177 people, healthy volunteers welcome
- Sponsor
- Bayer
Contraception
Evaluation of Participant Responses to Educational Counseling About Different Combined Hormonal Contraceptive Choices (P06557)
Physicians counsel women participants who are candidates for hormonal contraception about available combined hormonal contraceptive methods (the combined pill, the contraceptive vaginal ring [i.e., the etonogestrel +…
- Trial name
- ECOS (NCT01181778)
- Volunteers
- 1,919 people, healthy volunteers welcome
- Sponsor
- Organon and Co
Change in Bone Mineral Density, Bone Loss
LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women
The primary objective of this study is to evaluate the impact of LF111 and drospirenone (DRSP) 3.5 mg chewable tablets on bone mineral density (BMD) at the lumbar spine after 12 months (13 medication cycles) of investigation in…
- Trial name
- NCT05303636
- Testing
- drospirenone 4 mg oral tablet or drospirenone 3.5 mg chewable tablet
- Where
- 37 sites in United States, Czechia and 1 more
- Volunteers
- 1,536 people, healthy volunteers welcome
- Sponsor
- Insud Pharma
Contraception, Female Contraception
A Comparative Pharmacokinetic Study of ORTHO EVRA (a Transdermal Contraceptive Patch) and CILEST (an Oral Contraceptive) in Healthy Female Volunteers
The objective of this study is to compare the levels of the hormones norelgestromin, norgestrel, and ethinyl estradiol in the bloodstream of healthy female volunteers administered ORTHO EVRA® (a transdermal contraceptive patch)…
- Trial name
- NCT00254865
- Testing
- EVRA® transdermal contraceptive patch containing 6 mg of norelgestromin and 0.75 mg of ethinyl estradiol (versus CILEST® tablets).
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Contraception, Female Contraception
A Study of Efficacy and Safety With the Transdermal Contraceptive System.
The purpose of the study is to evaluate the contraceptive efficacy, safety, cycle control, and compliance with the transdermal contraceptive system.
- Trial name
- NCT00236769
- Testing
- norelgestromin + ethinyl estradiol
- Volunteers
- 1,751 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Contraception, Female Contraception
A Study to Evaluate the Exposure of Norelgestromin and Ethinyl Estradiol From Commercial Lots of EVRA (a Transdermal Contraceptive Patch Manufactured by LOHMANN Therapie-Systeme) and CILEST (an Oral Contraceptive)
The objective of this study is to estimate exposure to the hormones norelgestromin, norgestrel, and ethinyl estradiol in healthy female volunteers across multiple commercial lots of EVRA® (a transdermal contraceptive patch…
- Trial name
- NCT00258063
- Testing
- EVRA® transdermal contraceptive patch containing 6 mg of norelgestromin and 0.60 mg of ethinyl estradiol (versus CILEST® tablets).
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Contraception, Bone Density
Depo-Provera: Bone Mineral Density and Total Body Calcium in Adolescent DP150CI Users and Non-Hormonal Contraception
To evaluate and compare Bone Mineral Density (BMD) in adolescent Depo-Provera Contraceptive Injection (DP150CI) users during depo medroxyprogesterone acetate (DMPA) therapy and following discontinuation of DMPA.
- Trial name
- NCT00139685
- Testing
- Depo-Provera Contraceptive Injection - DP150CI
- Where
- 12 sites in United States
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- Pfizer
Contraception, Birth Control
Safety of a Contraceptive Copper Vaginal Ring
Many birth control options today come with unwanted side effects or risks. Hormonal methods can affect both mental and physical health, while devices like copper IUDs carry risks such as uterine perforation or infection.
- Conditions
- Contraception, Birth Control, Pregnancy Prevention
- Trial name
- NCT07666997
- Testing
- Vaginal Ring
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Elle, MD Biotechnologies Inc.